Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology
-$0.04 today
- Market cap
- $212.10M
- Beta
- 1.51
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 1.22M
Average 1.19M
LCTX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Lineage Cell Therapeutics, Inc.AMEX: LCTX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was -$7.94M, compared with -$2.68M a year earlier.
Context
- Accumulated OCI amounted to 7.3% of total assets at the end of Q1 FY2026, up 4.9 pp from a year earlier.
- Accumulated OCI grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -196.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (3.92M) USD
- Year-over-year change
- -36.3%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.92M) | -36.3% |
| FY2024 | 2024-12-31 | (2.88M) | +6.3% |
| FY2023 | 2023-12-31 | (3.07M) | +14.1% |
| FY2022 | 2022-12-31 | (3.57M) | +31.5% |
| FY2021 | 2021-12-31 | (5.21M) | — |
Accumulated OCI vs competitors
How LCTX compares with its peers on the latest reported figures
- LCTX's Mar 2026 Accumulated OCI of -$7.94M is the lowest of the 4 companies compared; the peer median is $0.
- Its year-over-year change of -196.2% is the 3rd highest of 4, against a peer median of +6.6%.
- Accumulated OCI amounts to 7.3% of total assets for LCTX, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $106.03M | +6.6% | +13.0% | 13.7% | |
| Dec 2025 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | -$585K | -291.8% | — | 0.2% | |
| Mar 2026 | -$7.94M | -196.2% | — | 7.3% | |
| Peer median (excluding LCTX) | $0 | +6.6% | +13.0% | 0.2% | |
Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55.74M | 11.36M | 35.44M | 45.79M | 40.79M |
| Short-term Investments | 2.62M | 46.52M | 50K | 2.02M | 14.99M |
| Net Receivables | 51.14M | 297K | 745K | 638K | 1.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.05M | 1.83M | 2.2M | 2.55M | 1.81M |
| Total Current Assets | 111.55M | 60M | 38.44M | 51M | 59.16M |
| Property, Plant & Equipment (Net) | 4.87M | 5.67M | 4.77M | 4.4M | 4.7M |
| Goodwill | 10.67M | 10.67M | 10.67M | 10.67M | 10.67M |
| Intangible Assets | 46.82M | 46.69M | 46.56M | 46.54M | 31.7M |
| Long-term Investments | 0 | 581K | 0 | 0 | 0 |
| Tax Assets | 0 | (581K) | 0 | 0 | 5.8M |
| Other Non-current Assets | 630K | 627K | 577K | 614K | 558K |
| Total Non-current Assets | 63M | 63.66M | 62.58M | 62.22M | 53.43M |
| Total Assets | 174.55M | 123.66M | 101.02M | 113.22M | 112.58M |
| Account Payables | 3.54M | 2.39M | 2.05M | 1.17M | 2.34M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 18.12M | 9.42M | 10.81M | 7.39M | 3.33M |
| Other Current Liabilities | 2.54M | 3.83M | 3.12M | 3.07M | 3.74M |
| Total Current Liabilities | 47.12M | 18.98M | 17.96M | 13.98M | 11.37M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 2.08M | 2.08M | 273K | 273K | 22K |
| Deferred Revenue (Non-current) | 32.45M | 27.73M | 18.69M | 14.43M | 12.38M |
| Other Non-current Liabilities | 30K | 2K | 0 | 6.16M | 43.91M |
| Total Non-current Liabilities | 36.53M | 32.75M | 21.04M | 22.23M | 57.87M |
| Total Liabilities | 83.65M | 51.73M | 39M | 36.21M | 69.24M |
| Common Stock | 434.53M | 440.28M | 451.34M | 484.72M | 515.47M |
| Retained Earnings | (337.1M) | (363.37M) | (384.86M) | (403.47M) | (467M) |
| Accumulated OCI | (5.21M) | (3.57M) | (3.07M) | (2.88M) | (3.92M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (1.32M) | (1.4M) | (1.4M) | (1.37M) | (1.2M) |
| Total Equity | 90.9M | 71.94M | 62.02M | 77.01M | 43.35M |
| Total Debt | 2.8M | 3.9M | 2.95M | 2.51M | 2.42M |
| Net Debt | (52.94M) | (7.46M) | (32.49M) | (43.28M) | (38.37M) |
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.